top of page
  • Completed

NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)

Updated: Sep 15, 2022


A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)


German-speaking myeloma multicenter group

(GMMG)

GMMG-HD6 myeloma trial

Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment.


Sponsor

University of Heidelberg Medical Center


Information provided by (Responsible Party)

Prof. Dr. Hartmut Goldschmidt, University of Heidelberg Medical Center


German Study

 

ClinicalTrials.gov Identifier: NCT02495922

Official Title: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

First Posted: July 13, 2015

Click here for details on ClinicalTrials.gov


GMMG - The German Speaking Myeloma Multicenter Group

 

Elotuzumab : National Cancer Institute

Elotuzumab : MedlinePlus Drug Information

 

Drug: elotuzumab

Drug: Lenalidomide

Drug: Bortezomib

Drug: Dexamethasone

 

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

BMC Cancer; 2019 May

Learn more

 

731.AUTOLOGOUS TRANSPLANTATION: CLINICAL AND EPIDEMIOLOGICAL

NOVEMBER 5, 2021

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Blood (2021) 138 (Supplement 1): 486.

Learn more

 

Location

Germany





186 views
Posts Archive
bottom of page